目的 探討注射用生長(zhǎng)抑素聯(lián)合多西他賽注射液和替吉奧膠囊治療進(jìn)展期胃癌的臨床療效。方法 抽取中國(guó)人民解放軍第八六醫(yī)院2013年1月-2015年12月收治的胃癌患者86例，隨機(jī)數(shù)字表格法將患者分為對(duì)照組和治療組，每組各43例。對(duì)照組第1天靜脈滴注多西他賽注射液75 mg/m²；口服替吉奧膠囊60 mg/m²，2次/d，于早飯后和晚飯后服用，連服21 d，之后停藥14 d，作為1個(gè)周期，干預(yù)2個(gè)周期。治療組在對(duì)照組基礎(chǔ)上第1~5天微泵注射用生長(zhǎng)抑素3 mg，持續(xù)6 h，2次/d，連續(xù)21 d，作為1個(gè)周期，干預(yù)2個(gè)周期。觀察兩組的臨床療效，比較兩組治療前后腫瘤標(biāo)志物和血管內(nèi)皮生長(zhǎng)因子水平以及毒副反應(yīng)情況。結(jié)果 治療后，對(duì)照組、治療組的近期有效率分別為69.77%、88.37%，兩組近期有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組CA199、CEA、CA724水平均明顯降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療組CA199、CA724水平降低程度明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清VEGF-A、VEGF-C、VEGF-D水平均明顯下降，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療組這些觀察指標(biāo)的降低程度明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者血小板減少、中性粒細(xì)胞減少、惡心嘔吐、肝損傷、腹瀉不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 注射用生長(zhǎng)抑素聯(lián)合多西他賽注射液和替吉奧膠囊治療進(jìn)展期胃癌具有較好的臨床療效，明顯降低腫瘤標(biāo)志物、血清血管內(nèi)皮生長(zhǎng)因子水平，減少不良反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To analyze the clinical effect of Somatostatin for injection combined with Docetaxel Injection and Tegafur Capsules in treatment of advanced gastric cancer. Methods Patients (86 cases) with advanced gastric cancer in No. 86 Hospital of PLA from January 2013 to December 2015 were divided into the control and treatment groups by random number table, and each group had 43 cases. The patients in the control group were iv administered with Docetaxel Injection in the first day, 75 mg/m². And they were po administered with Tegafur Capsules after breakfast and after dinner, 60 mg/m², twice daily, and treated for 21 d, then were repeated the next course of treatment after 4 d rest. The patients in the treatment group were micropump administered with Somatostatin for injection on the basis of the control group, 3 mg for 6 h, twice daily, 21 d for a course of treatment. The patients in two groups were treated for two courses. After treatment, clinical efficacy was evaluated, and tumor marker levels, serum VEGF levels and adverse reactions in two groups before and after treatment were compared. Results After treatment, the short-term efficacies in the control and treatment groups were 69.77% and 88.37%, respectively, and there was significant difference between groups (P<0.05). After treatment, the levels of CA199, CEA, CA724, serum VEGF-A, VEGF-C and VEGF-D were significantly decreased, and the differences were statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). There were no significant on adverse reaction rates of thrombocytopenia, thrombocytopenia, nausea and vomiting, liver injury, and diarrhea between two groups. Conclusion Somatostatin for injection combined with Docetaxel Injection and Tegafur Capsules has a significant clinical efficacy in treatment of advanced gastric cancer, can decrease tumor marker levels, serum VEGF levels, and reduce adverse reaction, which has a certain clinical application value.